Daré Bioscience (NASDAQ:DARE) Stock Crosses Below 200-Day Moving Average of $4.76

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.76 and traded as low as $3.05. Daré Bioscience shares last traded at $3.09, with a volume of 86,811 shares changing hands.

Analyst Upgrades and Downgrades

DARE has been the subject of several research reports. Brookline Capital Management upgraded Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Wednesday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of Daré Bioscience in a research report on Wednesday, May 15th.

Daré Bioscience Stock Down 14.9 %

The firm has a market capitalization of $26.02 million, a PE ratio of -0.80 and a beta of 1.37. The business has a 50-day moving average price of $4.70 and a 200-day moving average price of $4.76.

Daré Bioscience (NASDAQ:DARE) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.12). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. During the same period in the prior year, the firm posted ($1.08) EPS. On average, equities research analysts anticipate that Daré Bioscience, Inc. will post -2.76 earnings per share for the current year.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.